echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Medicines Company News > Hebei Renhe Yikang Pharmaceutical Sodium Valproate Injection Enters the Administrative Approval Stage and Will Be Approved

    Hebei Renhe Yikang Pharmaceutical Sodium Valproate Injection Enters the Administrative Approval Stage and Will Be Approved

    • Last Update: 2021-03-26
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
      Medical Network News on March 24 Recently, Hebei Renhe Yikang Pharmaceutical entered the administrative examination and approval stage with the imitation of 3 types of sodium valproate injection, which is expected to be approved in the near future and won the first imitation in China.
    Sodium valproate is the leading product in the domestic antiepileptic drug market.
    According to data from Meinenet, the sales of terminal sodium valproate in China's public medical institutions exceeded 2 billion yuan in 2019, and injections accounted for 64.
    56% of the market share.
     
      Sodium valproate is a nitrogen-free broad-spectrum antiepileptic drug, which can competitively inhibit Y-aminobutyric acid transaminase and increase the concentration of Y-aminobutyric acid to achieve anticonvulsant effects.
    Localized grand mal, grand mal and mixed epilepsy are all effective, and it is mostly used clinically for various epilepsy where other antiepileptic drugs are ineffective.
     
      Sales of terminal sodium valproate in China's public medical institutions
      Source: Mi Nei.
    com, China's public medical institutions terminal competition pattern
     
      Sodium valproate is the leading product in the domestic antiepileptic drug market, and its marketed dosage forms include injections, sustained-release tablets, ordinary tablets and solutions.
    According to data from Menet.
    com, in 2019, the
    sales of terminal sodium valproate in China's urban public
    hospitals , county-level public hospitals, urban community centers, and township health centers (Chinese public medical institutions) exceeded 2 billion yuan, and injections accounted for 64.
    56% of the market share.
    .
     
      Market application status of sodium valproate injection
      Source: One-click search on Mi Nei.
    com
     
      Currently, only the domestic market sales of injectable sodium valproate sodium valproate injection products, manufacturers, including Sanofi, Shenyang Pharmaceutical Malaysia and four-Chuankeruide pharmaceutical and other three companies .
    Sodium valproate injection has not yet been approved for listing.
    Fuan Pharmaceutical, Xi'an Yuanda Detian Pharmaceutical, Hebei Renheyikang Pharmaceutical, and Sichuan Creed Pharmaceuticals use imitations of sodium valproate injection.
    3 types of production.
     
      Hebei Renhe Yikang Pharmaceutical's registration status for this product has been changed to "under approval".
    If it is successfully approved, it will be deemed to have been reviewed and won the first domestic imitation.
     
      Source: Minet database
      Medical Network News on March 24 Recently, Hebei Renhe Yikang Pharmaceutical entered the administrative examination and approval stage with the imitation of 3 types of sodium valproate injection, which is expected to be approved in the near future and won the first imitation in China.
    Sodium valproate is the leading product in the domestic antiepileptic drug market.
    According to data from Meinenet, the sales of terminal sodium valproate in China's public medical institutions exceeded 2 billion yuan in 2019, and injections accounted for 64.
    56% of the market share.
     
      Sodium valproate is a nitrogen-free broad-spectrum antiepileptic drug, which can competitively inhibit Y-aminobutyric acid transaminase and increase the concentration of Y-aminobutyric acid to achieve anticonvulsant effects.
    Localized grand mal, grand mal and mixed epilepsy are all effective, and it is mostly used clinically for various epilepsy where other antiepileptic drugs are ineffective.
     
      Sales of terminal sodium valproate in China's public medical institutions
      Source: Mi Nei.
    com, China's public medical institutions terminal competition pattern
     
      Sodium valproate is the leading product in the domestic antiepileptic drug market, and its marketed dosage forms include injections, sustained-release tablets, ordinary tablets and solutions.
    According to data from Menet.
    com, in 2019, the
    sales of terminal sodium valproate in China's urban public
    hospitals , county-level public hospitals, urban community centers, and township health centers (Chinese public medical institutions) exceeded 2 billion yuan, and injections accounted for 64.
    56% of the market share.
    .
     
      Market application status of sodium valproate injection
      Source: One-click search on Mi Nei.
    com
     
      Currently, only the domestic market sales of injectable sodium valproate sodium valproate injection products, manufacturers, including Sanofi, Shenyang Pharmaceutical Malaysia and four-Chuankeruide pharmaceutical and other three companies .
    Sodium valproate injection has not yet been approved for listing.
    Fuan Pharmaceutical, Xi'an Yuanda Detian Pharmaceutical, Hebei Renheyikang Pharmaceutical, and Sichuan Creed Pharmaceuticals use imitations of sodium valproate injection.
    3 types of production.
     
      Hebei Renhe Yikang Pharmaceutical's registration status for this product has been changed to "under approval".
    If it is successfully approved, it will be deemed to have been reviewed and won the first domestic imitation.
     
      Source: Minet database
      Medical Network News on March 24 Recently, Hebei Renhe Yikang Pharmaceutical entered the administrative examination and approval stage with the imitation of 3 types of sodium valproate injection, which is expected to be approved in the near future and won the first imitation in China.
    Sodium valproate is the leading product in the domestic antiepileptic drug market.
    According to data from Meinenet, the sales of terminal sodium valproate in China's public medical institutions exceeded 2 billion yuan in 2019, and injections accounted for 64.
    56% of the market share.
     
      Sodium valproate is a nitrogen-free broad-spectrum antiepileptic drug, which can competitively inhibit Y-aminobutyric acid transaminase and increase the concentration of Y-aminobutyric acid to achieve anticonvulsant effects.
    Localized grand mal, grand mal and mixed epilepsy are all effective, and it is mostly used clinically for various epilepsy where other antiepileptic drugs are ineffective.
     
      Sales of terminal sodium valproate in China's public medical institutions
      Source: Mi Nei.
    com, China's public medical institutions terminal competition pattern
     
      Sodium valproate is the leading product in the domestic antiepileptic drug market, and its marketed dosage forms include injections, sustained-release tablets, ordinary tablets and solutions.
    According to data from Menet.
    com, in 2019, the
    sales of terminal sodium valproate in China's urban public
    hospitals , county-level public hospitals, urban community centers, and township health centers (Chinese public medical institutions) exceeded 2 billion yuan, and injections accounted for 64.
    56% of the market share.
    .
    Hospital hospital hospital
     
      Market application status of sodium valproate injection
      Source: One-click search on Mi Nei.
    com
     
      Currently, only the domestic market sales of injectable sodium valproate sodium valproate injection products, manufacturers, including Sanofi, Shenyang Pharmaceutical Malaysia and four-Chuankeruide pharmaceutical and other three companies .
    Sodium valproate injection has not yet been approved for listing.
    Fuan Pharmaceutical, Xi'an Yuanda Detian Pharmaceutical, Hebei Renheyikang Pharmaceutical, and Sichuan Creed Pharmaceuticals use imitations of sodium valproate injection.
    3 types of production.
    Enterprise business enterprise
     
      Hebei Renhe Yikang Pharmaceutical's registration status for this product has been changed to "under approval".
    If it is successfully approved, it will be deemed to have been reviewed and won the first domestic imitation.
     
      Source: Minet database
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.